Morgantown, WV -– (OTCQB: PRGB) (“Protea”) announced today that Princeton University has purchased

Protea’s LAESI DP-1000 Instrument System for direct molecular analysis. The system will

be used in Princeton’s Frick Chemistry Laboratory for the screening of microbial samples to

identify new molecular entities that may hold promise as new antimicrobial therapeutics.

“We are pleased that Princeton’s Frick Chemistry Laboratory will be applying our proprietary

LAESI technology to the discovery of novel antimicrobials and other therapeutic molecules;

this is a field that is today of critical importance to the pharmaceutical industry and to global

human health”, stated Steve Turner, Protea’s CEO.

“Bacteria use a wide range of small molecules to detect and respond to their environment

and to communicate, collaborate, or compete with other microbes. The small molecules

underlying this complex chemical language, their functions and biosynthetic pathways,

comprise the primary focus of our research efforts, and Protea’s DP-1000 system is an ideal

analytical tool that will benefit various aspects of our work,” stated Mohammad

Seyedsayamdost, PhD., Associate Professor of Chemistry, Princeton University. He

continued, “This group of small molecules has traditionally served as a prolific source of

drugs or drug leads, therefore, our studies will also aim to identify therapeutically useful

small molecules.”

The LAESI DP-1000 Instrument System allows the direct identification of molecules in living

cells and microbial samples, with analysis completed in seconds to minutes.

About Protea Biosciences Group, Inc.

Protea Biosciences Group, Inc. (OTCQB:PRGB) is a molecular information company

providing innovative bioanalytical solutions to the pharmaceutical, agricultural, and life

science industries. Protea has developed a new, fully automated, molecular information

technology platform, known as “LAESI” (Laser Ablation Electrospray Ionization), that

enables the direct analysis of molecules without the need for sample preparation. Large

molecular datasets are generated on native biological samples that can also be visually

displayed as 2D and 3D images. Protea maintains its own laboratory facilities where

services are provided to its clients, using LAESI and complementary technologies and

expertise.Protea Biosciences Group, Inc.

955 Hartman Run Road

Morgantown, WV 26507

P: 304.292.2226

F: 304.292.7101

www.proteabio.com

Forward-Looking Statements

This press release may contain certain statements relating to future results, which are forward

looking statements. These statements are not historical facts, but instead represent only the

company’s belief regarding future events, many of which, by their nature, are inherently uncertain

and outside of the company’s control. It is possible that the company’s actual results and financial

condition may differ, possibly materially, from the anticipated results and financial condition indicated

in these forward-looking statements. Further, information concerning the company and its business,

including factors that potentially could materially affect the company’s financial results, are contained

in the company’s filings with the Securities and Exchange Commission. All forward-looking

statements included in this press release are made only as of the date of this press release, and we

do not undertake any obligation to publicly update or correct any forward-looking statements to

reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more Information:

Protea Biosciences Group, Inc., 955 Hartman Run Road, Morgantown, WV 26505 USA

Phone: 304.292.2226 Fax: 304.292.7101

haddon.goodman@proteabio.com

https://proteabio.com/investors

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.